Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

Literature DB >> 16705208

Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H).

C Hirst, S Raasch, G Llewelyn, N Robertson.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2006 PMID： 16705208 PMCID： PMC2077476 DOI： 10.1136/jnnp.2005.076869

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

× No keyword cloud information.

6 in total

Review 1. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors: R A Hughes; A V Swan; P A van Doorn
Journal: Cochrane Database Syst Rev Date: 2003

2. Rituximab-responsive CIDP.

Authors: C Briani; G Zara; R Zambello; L Trentin; M Rana; F Zaja
Journal: Eur J Neurol Date: 2004-11 Impact factor: 6.089

3. Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation.

Authors: I Avivi; S Chakrabarti; P Kottaridis; C Kyriaku; A Dogan; D W Milligan; D Linch; A H Goldstone; S Mackinnon
Journal: Bone Marrow Transplant Date: 2004-07 Impact factor: 5.483

4. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases.

Authors: L H Van den Berg; I Mollee; J H Wokke; T Logtenberg
Journal: J Neuroimmunol Date: 1995-04 Impact factor: 3.478

5. Reshaping human antibodies for therapy.

Authors: L Riechmann; M Clark; H Waldmann; G Winter
Journal: Nature Date: 1988-03-24 Impact factor: 49.962

6. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Authors: A J Coles; M G Wing; P Molyneux; A Paolillo; C M Davie; G Hale; D Miller; H Waldmann; A Compston
Journal: Ann Neurol Date: 1999-09 Impact factor: 10.422

6 in total

11 in total

1. Pathogenesis and treatment of immune-mediated neuropathies.

Authors: Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal: Ther Adv Neurol Disord Date: 2009-07 Impact factor: 6.570

Review 2. Molecularly targeted therapies for dysimmune neuropathies.

Authors: Andreas A Argyriou
Journal: Mol Med Date: 2009-05-05 Impact factor: 6.354

Review 3. Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors: Thomas B Toothaker; Thomas H Brannagan
Journal: Curr Neurol Neurosci Rep Date: 2007-01 Impact factor: 5.081

Review 4. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors: Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal: Cochrane Database Syst Rev Date: 2017-05-08

Review 5. Immune-mediated neuropathies.

Authors: Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal: Nat Rev Dis Primers Date: 2018-10-11 Impact factor: 52.329